Luvomeran
RNA / oligonucleotide
Also known as VX-522
Evidence outlook · program status
Discontinued (2026-05-04), on a safety finding
Vertex discontinued the Phase 1/2 study of VX-522 (luvomeran), the inhaled CFTR mRNA candidate developed with Moderna, on 4 May 2026. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05668741 NCT05668741 · Cystic Fibrosis Registry: NCT05668741 | 1/2 | Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Day 1 Through Week 8 [SAD and MAD]) 2026-04-21 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Cystic Fibrosis: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Luvomeran: this drug | Discontinued | RNA / oligonucleotide | CFTR (mRNA replacement) | not yet graded | No reviewed efficacy summary in this indication | |
| Elexacaftor / Tezacaftor / Ivacaftor (Trikafta) | Approved | Small molecule | CFTR, CFTR | Reliable signal | NCT03525444: Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results). NCT03525548: Absolute change in ppFEV1 from baseline at Week 4 vs tezacaftor/ivacaftor: +10.4 vs +0.4; treatment difference 10.0 percentage points (95% CI 7.4 to 12.6), P<0.0001 (TRIKAFTA label section 14.1; CT.gov posted results). | |
| Ivacaftor (Kalydeco) | Approved | Small molecule | CFTR | Partial signal | NCT00909727: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1) NCT00909532: Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo -0.2 percent of predicted volume (L) (Standard Error 0.7) | 150 mg Ivacaftor q12h 10.4 percent of predicted volume (L) (Standard Error 0.7) | |
| Lumacaftor (Orkambi) | Approved | Small molecule | CFTR | Reliable signal | No reviewed efficacy summary in this indication | |
| Tezacaftor / Ivacaftor (Symdeko) | Approved | Small molecule | CFTR | not yet graded | No reviewed efficacy summary in this indication | |
| Vanzacaftor / Tezacaftor / Deutivacaftor (Alyftrek) | Approved | Small molecule | CFTR, CFTR | Reliable signal | No reviewed efficacy summary in this indication | |
| KB407 | Phase 1 | Gene therapy / editing | CFTR (gene replacement) | not yet graded | No reviewed efficacy summary in this indication | |
| VX-828 | Phase 1 | Small molecule | CFTR | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.